ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P80-17 New Drug-Related PA with QL Criteria: Bonjesta, Diclegis
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 12, 2017
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2521 - 2530 လၢ 4296 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P67-18 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Medical Policies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P47-18 New Medical Drug-Related Prior Authorization Requirements for Takhzyro (Lanadelumab-flyo)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P81-17 New Drug-Related PA Criteria: Opioid Induced Constipation (OIC)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 12, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P35-18 Update: Change to TPA Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P65-17 Clarification to Commercial Prior Authorization for Biologic Immunomodulators
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 06, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P39R1-18 Update: Blue Cross Contracts with eviCore to Expand Utilization Management for Post-Acute Care
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P2-18 New Medical Drug PA Requirements for Voretigene Neparvovec (Luxturna)
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 11, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P11-18 Minnesota Health Care Programs (MHCP) Reimbursement Rate for Vaccine Administration
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 02, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P41-17 PCA Agencies Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 17, 2017